JP5604520B2 - Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩 - Google Patents

Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩 Download PDF

Info

Publication number
JP5604520B2
JP5604520B2 JP2012528344A JP2012528344A JP5604520B2 JP 5604520 B2 JP5604520 B2 JP 5604520B2 JP 2012528344 A JP2012528344 A JP 2012528344A JP 2012528344 A JP2012528344 A JP 2012528344A JP 5604520 B2 JP5604520 B2 JP 5604520B2
Authority
JP
Japan
Prior art keywords
compound
formula
treatment
acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012528344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504534A (ja
Inventor
レーバー，シュテファン
ライト，マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2013504534A publication Critical patent/JP2013504534A/ja
Application granted granted Critical
Publication of JP5604520B2 publication Critical patent/JP5604520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012528344A 2009-09-11 2010-09-08 Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩 Active JP5604520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09170097.1 2009-09-11
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (2)

Publication Number Publication Date
JP2013504534A JP2013504534A (ja) 2013-02-07
JP5604520B2 true JP5604520B2 (ja) 2014-10-08

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528344A Active JP5604520B2 (ja) 2009-09-11 2010-09-08 Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩

Country Status (34)

Country Link
US (1) US8227491B2 (enExample)
EP (1) EP2475645B1 (enExample)
JP (1) JP5604520B2 (enExample)
KR (1) KR101382871B1 (enExample)
CN (1) CN102639506B (enExample)
AR (2) AR078352A1 (enExample)
AU (1) AU2010294277B2 (enExample)
BR (1) BR112012005511B8 (enExample)
CA (1) CA2771493C (enExample)
CL (1) CL2012000611A1 (enExample)
CO (1) CO6491033A2 (enExample)
CR (1) CR20120089A (enExample)
CY (1) CY1114377T1 (enExample)
DK (1) DK2475645T3 (enExample)
EC (1) ECSP12011723A (enExample)
ES (1) ES2423821T3 (enExample)
HR (1) HRP20130869T1 (enExample)
IL (1) IL217920A (enExample)
IN (1) IN2012DN00763A (enExample)
MA (1) MA33563B1 (enExample)
MX (1) MX2012002254A (enExample)
MY (1) MY161103A (enExample)
NZ (1) NZ597514A (enExample)
PE (1) PE20120863A1 (enExample)
PL (1) PL2475645T3 (enExample)
PT (1) PT2475645E (enExample)
RS (1) RS52987B (enExample)
RU (1) RU2541475C2 (enExample)
SG (1) SG179035A1 (enExample)
SI (1) SI2475645T1 (enExample)
TW (1) TWI412363B (enExample)
UA (1) UA107088C2 (enExample)
WO (1) WO2011029827A1 (enExample)
ZA (1) ZA201201599B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CN101155781B (zh) * 2005-04-06 2012-11-07 霍夫曼-拉罗奇有限公司 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物
CA2664119A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
BR112012005511A2 (pt) 2016-04-19
PL2475645T3 (pl) 2013-12-31
CN102639506B (zh) 2014-09-03
WO2011029827A1 (en) 2011-03-17
AR114032A2 (es) 2020-07-15
PT2475645E (pt) 2013-08-05
CO6491033A2 (es) 2012-07-31
JP2013504534A (ja) 2013-02-07
HRP20130869T1 (hr) 2013-10-25
KR20120048040A (ko) 2012-05-14
ECSP12011723A (es) 2012-04-30
EP2475645A1 (en) 2012-07-18
CA2771493A1 (en) 2011-03-17
US8227491B2 (en) 2012-07-24
SI2475645T1 (sl) 2013-10-30
MY161103A (en) 2017-04-14
RU2541475C2 (ru) 2015-02-20
CR20120089A (es) 2012-03-22
RU2012113924A (ru) 2013-10-20
ES2423821T3 (es) 2013-09-24
RS52987B (sr) 2014-02-28
BR112012005511B1 (pt) 2021-03-02
EP2475645B1 (en) 2013-07-03
IL217920A0 (en) 2012-03-29
AU2010294277B2 (en) 2015-07-09
MA33563B1 (fr) 2012-09-01
AU2010294277A1 (en) 2012-02-09
PE20120863A1 (es) 2012-07-23
DK2475645T3 (da) 2013-07-22
CN102639506A (zh) 2012-08-15
CY1114377T1 (el) 2016-08-31
KR101382871B1 (ko) 2014-04-08
IN2012DN00763A (enExample) 2015-06-26
IL217920A (en) 2015-11-30
ZA201201599B (en) 2012-11-28
CA2771493C (en) 2017-08-29
BR112012005511B8 (pt) 2021-05-25
US20110065759A1 (en) 2011-03-17
UA107088C2 (xx) 2014-11-25
MX2012002254A (es) 2012-03-16
NZ597514A (en) 2013-10-25
AR078352A1 (es) 2011-11-02
TW201114427A (en) 2011-05-01
TWI412363B (zh) 2013-10-21
CL2012000611A1 (es) 2012-09-07
SG179035A1 (en) 2012-04-27
HK1172021A1 (en) 2013-04-12

Similar Documents

Publication Publication Date Title
JP5604520B2 (ja) Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩
JP2010529196A (ja) アザペプチド誘導体
WO2021233133A1 (zh) 用作ret激酶抑制剂的化合物及其应用
KR20220035950A (ko) 염증성 기도 질환 또는 섬유성 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 n-메틸, n-(6-(메톡시)피리다진-3-일) 아민 유도체
JP2024510778A (ja) １，３－置換シクロブチル誘導体及びその使用
JP5815876B2 (ja) ５−シクロアルキル−又は５−ヘテロシクリル−ニコチンアミド類
JP2010511034A (ja) 第Ｘａ因子阻害剤としての（Ｒ）−５−メチル−４，５−ジヒドロ−ピラゾール−１，５−ジカルボン酸１−［（４−クロロ−フェニル）−アミド］５−｛［２−フルオロ−４−（２−オキソ−２Ｈ−ピリジン−１−イル）−フェニル］−アミド｝
JP5442711B2 (ja) Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体
EP2874628A2 (en) Salts and hydrates of antipsychotics
JP5815875B2 (ja) Ｎ−（５−シクロアルキル−又は５−ヘテロシクリル）−ピリジン−３−イルカルボキサミド
HK1172021B (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents
HK40082417A (en) Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
JPH06184113A (ja) アゼピン誘導体、その製造法およびその用途
HK1193599B (en) N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140825

R150 Certificate of patent or registration of utility model

Ref document number: 5604520

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250